LL-37 and Vitamin D: The Immune Connection

At a Glance

Why Does Vitamin D Affect Your Immune System?

For decades, the medical establishment treated vitamin D and immune modulation as a bone health nutrient — important for calcium absorption and preventing rickets, but not much else. This was wrong. Spectacularly wrong.

The discovery that vitamin D directly regulates the expression of antimicrobial peptides — particularly LL-37 — fundamentally changed our understanding of how the immune system works. It explained why vitamin D deficiency is associated with increased susceptibility to infections, why infections like tuberculosis are more severe in people with low vitamin D, and why seasonal variations in vitamin D correlate with seasonal patterns of respiratory illness.

This is not speculative biology. This is a well-characterized molecular pathway confirmed by multiple independent research groups. Here is what the evidence shows.

The Vitamin D-LL-37 Pathway

The Molecular Mechanism

The connection between vitamin D and LL-37 is direct and well-characterized:

1. Vitamin D3 (cholecalciferol) is converted to its active form, 1,25-dihydroxyvitamin D3 (calcitriol), by the enzyme 1-alpha-hydroxylase.

2. Calcitriol binds to the vitamin D receptor (VDR), a nuclear receptor present in virtually all immune cells — macrophages, dendritic cells, T-cells, B-cells, and epithelial cells.

3. The activated VDR forms a complex with retinoid X receptor (RXR) and binds to a vitamin D response element (VDRE) in the promoter region of the CAMP gene (cathelicidin antimicrobial peptide gene).

4. This transcriptional activation induces expression of hCAP18, the precursor protein of LL-37.

5. hCAP18 is cleaved by proteinase 3 to produce the active 37-amino-acid antimicrobial peptide LL-37.

The entire pathway — from vitamin D to functional antimicrobial peptide — is dependent on adequate vitamin D levels. When vitamin D is insufficient, the VDR-mediated transcription of hCAP18 is impaired, and LL-37 production drops.

The Tuberculosis Discovery

The pivotal study was published by Liu et al. in 2006 in Science. The researchers investigated why African Americans — who have a higher prevalence of vitamin D deficiency due to melanin-mediated reduction in cutaneous vitamin D synthesis — are more susceptible to tuberculosis.

They discovered that when macrophages encounter Mycobacterium tuberculosis, they upregulate expression of both the vitamin D receptor and the 1-alpha-hydroxylase enzyme. This creates a local amplification loop: the immune cell, upon detecting the pathogen, enhances its own ability to respond to vitamin D. The resulting vitamin D-mediated induction of LL-37 was essential for killing the intracellular mycobacteria.

The critical finding: macrophages from vitamin D-deficient individuals could not mount this LL-37 response effectively. Adding vitamin D to the culture restored it. This was the smoking gun linking vitamin D deficiency to impaired antimicrobial defense through the LL-37 pathway.

Clinical Implications

Respiratory Infections

The vitamin D-LL-37 axis is particularly relevant to respiratory immunity because LL-37 is produced by airway epithelial cells and is present in airway surface liquid — the frontline defense against inhaled pathogens.

Multiple studies have confirmed the relationship:

Chronic Lyme Disease

This connection is directly relevant to the Lyme patient population. Many chronic Lyme disease treatment patients have suboptimal vitamin D levels, which may compound their immune impairment:

1. Impaired LL-37 production — reduced ability to disrupt Borrelia biofilms and kill planktonic bacteria
2. Reduced innate immune activation — vitamin D is required for optimal macrophage and dendritic cell function
3. Impaired T-cell function — vitamin D modulates both regulatory and effector T-cell activity

In my clinical practice, vitamin D optimization is one of the first interventions in any chronic Lyme protocol. It is simple, safe, inexpensive, and supported by strong evidence.

For more on LL-37’s role in Lyme disease, see LL-37 for Biofilm Disruption in Chronic Lyme.

Autoimmune Disease

The relationship between vitamin D, LL-37, and autoimmunity is more complex. LL-37 has been implicated in the pathogenesis of certain autoimmune conditions — it can form complexes with self-DNA and self-RNA that activate plasmacytoid dendritic cells through TLR9 and TLR7, driving type I interferon production. This mechanism has been demonstrated in psoriasis and systemic lupus erythematosus (SLE).

However, vitamin D itself is broadly immunoregulatory and generally suppresses autoimmune activity. The paradox — vitamin D increases LL-37, but LL-37 can contribute to autoimmunity while vitamin D suppresses it — has not been fully resolved. The current understanding is that vitamin D’s overall immunoregulatory effects are net-positive even in autoimmune conditions, and that the LL-37-mediated autoimmune mechanisms occur primarily when LL-37 encounters specific triggers (damaged tissue releasing self-nucleic acids) rather than from circulating LL-37 alone.

Optimal Vitamin D Levels for LL-37 Production

Standard vs. Optimal

The standard medical definition of “sufficient” vitamin D (30 ng/mL) was established primarily for bone health. The evidence suggests that immune-related functions — including LL-37 production — may require higher levels. In vitro studies show that LL-37 induction increases in a dose-dependent manner with vitamin D concentration up to approximately 50-80 ng/mL, above which the response plateaus.

What I Target in Practice

For patients whose primary concern is immune optimization — chronic infections, recurrent infections, chronic Lyme, autoimmune conditions — I target serum 25-hydroxyvitamin D levels of 50-80 ng/mL. This is above the standard “sufficient” threshold but well below the level at which toxicity occurs.

Vitamin D Supplementation Protocol

Getting to Optimal Levels

Critical Co-Factors

Vitamin D does not work in isolation. For optimal vitamin D metabolism and LL-37 production, the following co-factors are important:

Vitamin D3 vs. D2

Use vitamin D3 (cholecalciferol), not D2 (ergocalciferol). D3 is more effective at raising and maintaining serum 25-hydroxyvitamin D levels, has a longer half-life, and is the form naturally produced by human skin in response to UV-B radiation.

Synergy: Vitamin D + Exogenous LL-37

For patients using exogenous LL-37 (subcutaneous injection), optimizing vitamin D levels is not optional — it is foundational. The rationale:

1. Endogenous amplification. Adequate vitamin D ensures your body’s own LL-37 production is maximized. Exogenous LL-37 supplementation addresses the gap between what your body produces and what is needed therapeutically.

2. Immune priming. Vitamin D primes immune cells — macrophages, dendritic cells, T-cells — to respond more effectively. LL-37 then provides direct antimicrobial activity and biofilm disruption strategies. The combination is synergistic.

3. Sustained effect. Exogenous LL-37 has a limited half-life. Vitamin D-driven endogenous production provides a continuous baseline of LL-37 between exogenous doses.

In practice, I ensure vitamin D levels are optimized before or concurrently with initiating exogenous LL-37 therapy. Administering LL-37 to a vitamin D-deficient patient is like refueling one engine of a two-engine airplane — it helps, but it is not the full solution.

Beyond Infections: The Broader Vitamin D-LL-37 Connection

Cancer

LL-37 has demonstrated anti-tumor activity in several models, and vitamin D deficiency is associated with increased risk of several cancers. The vitamin D-LL-37 axis may represent one mechanism through which vitamin D exerts its observed anti-cancer effects — through LL-37-mediated immune surveillance.

Wound Healing

Vitamin D and LL-37 are both involved in wound healing. LL-37 promotes keratinocyte migration and angiogenesis at wound sites. Vitamin D deficiency impairs wound healing in clinical studies. The pathway is clear: adequate vitamin D ensures adequate LL-37 at wound sites.

Mental Health

Emerging research links vitamin D deficiency to depression and cognitive decline. LL-37 has neuroprotective properties. Whether the vitamin D-LL-37 axis contributes to the neurological effects of vitamin D deficiency is speculative but mechanistically plausible.

The Bottom Line

Vitamin D directly and dose-dependently regulates LL-37 production through a well-characterized molecular pathway. This connection explains much of vitamin D’s observed immune-protective effects and has direct clinical implications for infections, chronic Lyme disease, and immune optimization. Targeting serum vitamin D levels of 50-80 ng/mL — above standard sufficiency thresholds but well within the safe range — optimizes LL-37 production. Co-supplementation with vitamin K2, magnesium, and zinc supports the pathway. For patients using exogenous LL-37, vitamin D optimization is a foundational, not optional, component of the protocol.

For LL-37’s role in biofilm disruption, see LL-37 for Biofilm Disruption in Chronic Lyme. For the full overview, see LL-37: The Body’s Antimicrobial Peptide.

References

1. Liu PT, et al. “Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.” Science. 2006;311(5768):1770-1773. PMID: 16497887.
2. Wang TT, et al. “Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression.” J Immunol. 2004;173(5):2909-2912. PMID: 15322146.
3. Martineau AR, et al. “Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data.” BMJ. 2017;356:i6583. PMID: 28202713.
4. Gombart AF, et al. “Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3.” FASEB J. 2005;19(9):1067-1077. PMID: 15985530.
5. Jolliffe DA, et al. “Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials.” Lancet Diabetes Endocrinol. 2021;9(5):276-292. PMID: 33798465.

Disclaimer: This article is for educational purposes and reflects current published research and clinical observation. It is not medical advice. Vitamin D supplementation should be guided by serum level testing and physician oversight. Consult a qualified physician before pursuing any supplementation or peptide therapy.

Related Reading

• LL-37: The Antimicrobial Peptide for Innate Immunity
• The Vagus Nerve and Inflammation: Cholinergic Anti-Inflammatory Pathway